Advanced primary urethral cancer: a case report

[1]  M. Babjuk,et al.  The prognostic effect of salvage surgery and radiotherapy in patients with recurrent primary urethral carcinoma. , 2018, Urologic oncology.

[2]  A. Veerakumarasivam,et al.  Immunohistochemical expression of NANOG in urothelial carcinoma of the bladder. , 2017, The Malaysian journal of pathology.

[3]  A. Roychoudhury,et al.  Outcomes and Prognostic Factors of Primary Urethral Cancer. , 2017, Urology.

[4]  A. Burnett,et al.  Urethral carcinoma in situ: recognition and management , 2017, International Urology and Nephrology.

[5]  L. Zinman,et al.  Management of Proximal Primary Urethral Cancer: Should Multidisciplinary Therapy Be the Gold Standard? , 2016, The Urologic clinics of North America.

[6]  C. Cohen,et al.  GATA3 immunohistochemical expression in invasive urothelial carcinoma. , 2016, Urologic oncology.

[7]  M. Abolhasani,et al.  Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: Analysis of CK20, CD44, P53 and Ki67 , 2016, Medical journal of the Islamic Republic of Iran.

[8]  P. Ditonno,et al.  A Challenging Surgical Approach to Locally Advanced Primary Urethral Carcinoma , 2016, Medicine.

[9]  A. Yıldırım,et al.  Prognostic significance of survivin, β-catenin and p53 expression in urothelial carcinoma. , 2015, Bosnian journal of basic medical sciences.

[10]  M. Kent,et al.  Combined chemoradiation as primary treatment for invasive male urethral cancer. , 2015, The Journal of urology.

[11]  M. Babjuk,et al.  Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma , 2015, World Journal of Urology.

[12]  J. Witjes,et al.  EAU guidelines on primary urethral carcinoma. , 2013, European urology.

[13]  Haitao Liu,et al.  [Expression of Engrailed-2 and β-catenin in bladder urothelial carcinoma and their significance]. , 2013, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

[14]  O. Visser,et al.  Primary urethral carcinoma in females: an epidemiologic study on demographical factors, histological types, tumour stage and survival , 2013, World Journal of Urology.

[15]  J. Adolfsson,et al.  Incidence and survival of rare urogenital cancers in Europe. , 2012, European journal of cancer.

[16]  R. Haba,et al.  Expression of vimentin and high‐molecular‐weight cytokeratin (clone 34ßE12) in differentiating reactive renal tubular cells from low‐grade urothelial carcinoma cells in voided urine , 2011, Cytopathology : official journal of the British Society for Clinical Cytology.

[17]  F. Rabbani.  Prognostic factors in male urethral cancer , 2011, Cancer.

[18]  J. Blaivas,et al.  Urethral diverticula in women: discrepancies between magnetic resonance imaging and surgical findings. , 2010, The Journal of urology.

[19]  P. Schellhammer,et al.  Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra. , 2007, Clinical genitourinary cancer.

[20]  N. Weiss,et al.  Incidence of primary urethral carcinoma in the United States. , 2006, Urology.

[21]  F. Algaba,et al.  Intravesical instillations with bacillus calmette-guérin for the treatment of carcinoma in situ involving prostatic ducts. , 2006, European urology.

[22]  S. Shariat,et al.  Stage specific lymph node metastasis mapping in radical cystectomy specimens. , 2004, The Journal of urology.

[23]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[24]  L. Lacombe,et al.  Female urethral carcinoma: an analysis of treatment outcome and a plea for a standardized management strategy. , 1998, British journal of urology.